Fig. 2: Effects of senolytics on cardiometabolic diseases. | npj Aging

Fig. 2: Effects of senolytics on cardiometabolic diseases.

From: Cell senescence in cardiometabolic diseases

Fig. 2

Summary of the beneficial effects (+) or side effects (−) of the senolytic drugs D + Q and ABT-263 in cardiometabolic diseases. Senolytics reduce the senescent cell burden and improve disease outcome in multiple diseases such as atherosclerosis, HFpEF, MetS, DCM and age-related cardiac remodeling. However, in some cases, immunosuppressive side effects of senolytic drugs have been described (e.g. leukocytopenia, thrombocytopenia) which challenges their translation to the clinic. BNP brain natriuretic peptide, CPC cardiac progenitor cells, DCM diabetic cardiomyopathy, D + Q dasatinib + quercetin, HFpEF heart failure with preserved ejection fraction, MetS metabolic syndrome.

Back to article page